{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:39:44Z","timestamp":1780637984838,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100012266","name":"Norsk Revmatikerforbund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Calpro AS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40744-022-00464-7","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:04:03Z","timestamp":1653041043000},"page":"1171-1179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-2840","authenticated-orcid":false,"given":"Brigitte","family":"Michelsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine Thomassen","family":"Berget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-5830","authenticated-orcid":false,"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9279-5191","authenticated-orcid":false,"given":"Glenn","family":"Haugeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"464_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/BOR.0000000000000284","volume":"28","author":"JS Smolen","year":"2016","unstructured":"Smolen JS. Treat-to-target as an approach in inflammatory arthritis. Curr Opin Rheumatol. 2016;28:297\u2013302.","journal-title":"Curr Opin Rheumatol"},{"key":"464_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/rheumatology\/kex474","volume":"57","author":"A Balsa","year":"2018","unstructured":"Balsa A, Sanmarti R, Rosas J, et al. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. Rheumatology (Oxford). 2018;57:688\u201393.","journal-title":"Rheumatology (Oxford)"},{"key":"464_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31:299\u2013316.","journal-title":"BioDrugs"},{"key":"464_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/rheumatology\/kev356","volume":"55","author":"PD Kiely","year":"2016","unstructured":"Kiely PD. Biologic efficacy optimization\u2014a step towards personalized medicine. Rheumatology (Oxford). 2016;55:780\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"464_CR5","doi-asserted-by":"publisher","first-page":"J258","DOI":"10.1016\/j.jaut.2009.12.003","volume":"34","author":"Y Arnson","year":"2010","unstructured":"Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010;34:J258\u201365.","journal-title":"J Autoimmun"},{"key":"464_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.18632\/oncotarget.13613","volume":"8","author":"F Qiu","year":"2017","unstructured":"Qiu F, Liang CL, Liu H, et al. Impacts of cigarette smoking on immune responsiveness: up and down or upside down? Oncotarget. 2017;8:268\u201384.","journal-title":"Oncotarget"},{"key":"464_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13075-018-1659-z","volume":"20","author":"G Haugeberg","year":"2018","unstructured":"Haugeberg G, Michelsen B, Tengesdal S, Hansen IJW, Diamantopoulos A, Kavanaugh A. Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther. 2018;20:160.","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 11","key":"464_CR8","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1002\/acr.20577","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S64-85.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"464_CR9","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023\u201338.","journal-title":"Lancet"},{"key":"464_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13075-020-02190-3","volume":"22","author":"M Jarlborg","year":"2020","unstructured":"Jarlborg M, Courvoisier DS, Lamacchia C, et al. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020;22:105.","journal-title":"Arthritis Res Ther"},{"key":"464_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jim.2011.08.022","volume":"373","author":"C Lallemand","year":"2011","unstructured":"Lallemand C, Kavrochorianou N, Steenholdt C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods. 2011;373:229\u201339.","journal-title":"J Immunol Methods"},{"key":"464_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003348","volume":"17","author":"S H\u00e4ssler","year":"2020","unstructured":"H\u00e4ssler S, Bachelet D, Duhaze J, et al. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: a prospective multicohort study of the ABIRISK consortium. PLoS Med. 2020;17: e1003348.","journal-title":"PLoS Med"},{"key":"464_CR13","doi-asserted-by":"crossref","unstructured":"Brun MK, Goll GL, J\u00f8rgensen KK, et al. Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial. J Intern Med. 2022.","DOI":"10.1111\/joim.13495"},{"key":"464_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/rheumatology\/kev392","volume":"55","author":"B Glintborg","year":"2016","unstructured":"Glintborg B, H\u00f8jgaard P, Lund Hetland M, et al. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology (Oxford). 2016;55:659\u201368.","journal-title":"Rheumatology (Oxford)"},{"key":"464_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13075-016-1032-z","volume":"18","author":"J Inciarte-Mundo","year":"2016","unstructured":"Inciarte-Mundo J, Ramirez J, Hernandez MV, et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther. 2016;18:160.","journal-title":"Arthritis Res Ther"},{"key":"464_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/sji.12572","volume":"86","author":"LI Bader","year":"2017","unstructured":"Bader LI, Solberg SM, Kaada SH, et al. Assays for infliximab drug levels and antibodies: a matter of scales and categories. Scand J Immunol. 2017;86:165\u201370.","journal-title":"Scand J Immunol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00464-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-022-00464-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00464-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T07:28:53Z","timestamp":1658734133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-022-00464-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1007\/s40744-022-00464-7","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"assertion":[{"value":"22 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was supported by the Norwegian Rheumatism Association, who also funded the journal\u2019s Rapid Service Fee. The iLite\u2122 assay kits and Victor\u2122 X (PerkinElmer) luminometer were provided from Pfizer free of charge. The Calpro\u2122 (ALP) ELISA kits were donated from Calpro AS free of charge. Pfizer, Calpro, and the Norwegian Rheumatism Association had no influence on the data collection, statistical analyses, writing of the manuscript, or decision to submit.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All coauthors were responsible for study design. Brigitte Michelsen, Kristine Thomassen Berget, and Glenn Haugeberg were responsible for data acquisition. Brigitte Michelsen analyzed the data and wrote the first version of the manuscript. All authors critically revised the manuscript and approved the final version.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Brigitte Michelsen: Consultancy fees from Novartis. Grant\/research support from Novartis and Pfizer paid to employer. Kristine Thomassen Berget: None. Arthur Kavanaugh: None. Glenn Haugeberg: Unrestricted grant from Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The study was approved by the Regional Committees for Medical and Health Research Ethics mid-Norway (Ref. 2015\/1196\/REK midt). Written informed consent was obtained from each patient prior to inclusion in the study. The study was performed in accordance with the Helsinki Declaration.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"All data generated or analyzed during this study are included in this published article\/as supplementary information files.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}